Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 106825-81-4 | MDL No. : | MFCD03426306 |
Formula : | C5H9NO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | JUNOWSHJELIDQP-SCSAIBSYSA-N |
M.W : | 131.13 | Pubchem ID : | 12680089 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.8 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 33.61 |
TPSA : | 58.56 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -9.39 cm/s |
Log Po/w (iLOGP) : | 0.75 |
Log Po/w (XLOGP3) : | -3.23 |
Log Po/w (WLOGP) : | -1.32 |
Log Po/w (MLOGP) : | -3.44 |
Log Po/w (SILICOS-IT) : | -0.05 |
Consensus Log Po/w : | -1.46 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | 1.45 |
Solubility : | 3680.0 mg/ml ; 28.0 mol/l |
Class : | Highly soluble |
Log S (Ali) : | 2.57 |
Solubility : | 48800.0 mg/ml ; 372.0 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | 0.11 |
Solubility : | 170.0 mg/ml ; 1.29 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.23 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine In methanol at 64℃; for 7h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1: H2 / Pd black / methanol / 0.5 h 2: Et3N / methanol / 7 h / 64 °C |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | With N-ethyl-N,N-diisopropylamine In tetrahydrofuran; water at 90℃; for 18h; | 1 General procedure: General procedure B A solution of amino nucleophile (3 equiv.), triethylamine (10 equiv.), and Intermediate 1 (1 equiv.) was stirred in dioxane and water (2:1 ratio) at 90 °C until complete consumption of starting material was observed by LC/MS. The solution was diluted withiN hydrochloric acid and dichloromethane. The layers were then separated and thelayer was extracted with dichloromethane. The organics were combined, dried over magnesium sulfate, filtered, and the solvent was removed in vacuo. Purification yielded theproductThe title compound was prepared following general procedure B, except (R)-morpholine-3-carboxylic acid (4 equiv.) was the amine reactant, Hunig’s base (5 equiv.) was used instead of triethylamine, and the contents were heated to 90 °C for 18 h as a solution in THF/water (9:1). Solvent was removed under a stream of nitrogen, and the crude material was purified via reverse phase HPLC using a 20-51% acetonitrile/water (in 0.1% TFA) gradient to deliver the desired compound, Compound 1-95 (19 mg, 76% yield). 1H NMR (500 MHz, CD3OD) ö 8.81 (d, 1 H), 8.39 (d, 1 H), 7.57 (s, 1 H), 7.26 - 7.34 (m, 1 H),7.02 - 7.16 (m, 2 H), 6.93 (d, 2 H), 6.00 (s, 2 H), 5.26 - 5.59 (m, 1 H), 4.55 (d, 2 H), 4.04 (s, 1 H), 3.93 (dd, 1 H), 3.62 - 3.80 (m, 2 H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
3.19 g | With sodium hydrogencarbonate In tetrahydrofuran; water for 28h; | Preparation of (R)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)morpholine-3-carboxylic acid To a solution of (R)-morpholine-3-carboxylic acid (2 g, 15.25 mmol) in THF (50.8 mL) and water (25.4 mL) was added sodium bicarbonate (1.922 g, 22.88 mmol) and FMOC-OSU (5.14 g, 15.25 mmol). The resulting mixture was stirred for 28 h. Afterremoval of THF, the white suspension was diluted with sat.NaHCO3/water and ether.Filter through celite. Washed with water and ether. Separate ether and aqueous layer.The aqueous layer was acidified with 1 N HC1, extracted with ethyl acetate, washed withbrine, dried over Na2504, concentrated to give 3.19 g (R)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)morpholine-3 -carboxylic acid as white solid. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate In ethanol at 25℃; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate In ethanol at 25℃; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
25.22% | Stage #1: 2-((3R,4aR,6aS,7R,10bR)-3-cyclopentyl-6a,10b-dimethyl-8-methylidenedecahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)acetaldehyde; (3R)-morpholine-3-carboxylic acid With acetic acid In tetrahydrofuran at 45℃; for 1h; Stage #2: With sodium tris(acetoxy)borohydride In tetrahydrofuran at 45℃; for 8h; | (3R)-4-(2-((3R,4aR,6aS,7R,10bR))-3-cyclopentyl-6a,10b-dimethyl-8-methylene-decahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)ethyl)morpholine-3-carboxylic acid Step 1 (3R)-4-(2-((3R,4aR,6aS,7R,10bR))-3-cyclopentyl-6a,10b-dimethyl-8-methylene-decahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)ethyl)morpholine-3-carboxylic acid 2-((3R,4aR,6aS,7R,10bR)-3-cyclopentyl-6a,10b-dimethyl-8-methylene-decahydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)acetaldehyde (250.00 mg, 721.50 umol) was dissolved in tetrahydrofuran (20 mL), and (3R)-morpholine-3-carboxylic acid (100.29 mg, 764.79 umol) and acetic acid (525.00 mg, 8.74 mmol, 500.00 uL) were added successively, then stirred at 45° C. for 1 hour. Sodium borohydride-acetic acid (500.00 mg, 2.36 mmol) was added and stirred at 45° C. for 8 hours. The system was concentrated. The residue was separated by column chromatography (silica, dichloromethane/methanol=20/1 to 10/1) to give (3R)-4-(2-((3R,4aR,6aS,7R,10bR))-3-cyclopentyl-6a,10b-dimethyl-8-methylene-deca hydro-1H-naphtho[2,1-d][1,3]dioxin-7-yl)ethyl)morpholine-3-carboxylic acid 456 (84 mg, yield: 25.22%). MS m/z (ESI):462.1 [M+1] 1H NMR (400 MHz, MeOD) 4.88-4.83 (m, 1H), 4.76 (s, 1H), 4.70 (d, J=5.5 Hz, 1H), 4.16 (d, J=10.5 Hz, 1H), 4.08 (d, J=11.3 Hz, 1H), 4.01 (d, J=12.3 Hz, 1H), 3.78 (t, J=11.4 Hz, 1H), 3.69 (t, J=10.9 Hz, 1H), 3.55-3.42 (m, 3H), 3.02 (t, J=9.8 Hz, 1H), 2.75 (br. s., 1H), 2.49-2.30 (m, 2H), 2.24-1.38 (m, 18H), 1.35 (s, 3H), 1.31-1.21 (m, 3H), 0.84 (s, 3H). |
[ 66937-99-3 ]
Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 1187929-04-9 ]
(S)-Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 1187928-88-6 ]
(R)-Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 1807882-36-5 ]
trans-2-Methylmorpholine-3-carboxylic acid hydrochloride
Similarity: 0.76
[ 66937-99-3 ]
Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 1187929-04-9 ]
(S)-Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 1187928-88-6 ]
(R)-Morpholine-3-carboxylic acid hydrochloride
Similarity: 0.97
[ 741288-31-3 ]
Methyl (S)-3-Morpholinecarboxylate
Similarity: 0.95
[ 126264-49-1 ]
Methyl 3-Morpholinecarboxylate
Similarity: 0.95